Ocean Biomedical, Inc. is a biotechnology firm focused on developing novel therapies for infectious diseases and cancer. The company is leveraging its proprietary drug discovery platform to identify and advance treatments, particularly in underserved markets such as malaria and fibrosis.
Business Overview
Ocean Biomedical primarily generates revenue through research grants and partnerships with larger pharmaceutical firms, which fund the development of its drug candidates. The company has a competitive advantage due to its unique drug discovery platform that focuses on high unmet medical needs, allowing it to attract funding and collaboration opportunities.
Advancements in clinical trials for lead drug candidates, particularly in malaria and fibrosis
Partnership announcements with larger pharmaceutical companies
Regulatory approvals for drug candidates
Changes in funding availability for biotechnology research
Risk Factors
Regulatory changes affecting drug approval processes
Technological disruptions in drug discovery methods
Emergence of new competitors with similar drug candidates
Potential for larger pharmaceutical companies to outbid for talent and resources
High liquidity risk due to low current ratio (0.06)
Dependence on external funding sources for R&D
Macro Sensitivity
low - the biotechnology sector is generally less sensitive to economic cycles as healthcare spending remains relatively stable.
Interest rates impact the cost of capital for R&D funding, which can affect the company's ability to finance its projects. Higher rates could lead to increased financing costs, negatively impacting valuation multiples.
minimal - the company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
Profile
growth - investors looking for high-risk, high-reward opportunities in the biotech sector.
high - the stock has exhibited significant volatility, evidenced by a 1-year return of -95.7%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
